---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Place in treatment, anticipated use, and care setting. Topics: Summary: guideline recommendations for on-demand treatment, Summary: anticipated use of an oral on-demand option and care setting, Summary: patient and physician preference, Summary: payer criteria and quantity limits, and 23 further topics. 27 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: guideline recommendations for on-demand treatment

The guideline by Vázquez et al. recognizes four types of on-demand treatment as effective (intravenous C1-INH, icatibant, sebetralstat, and ecallantide), recommends intravenous C1-INH, icatibant, or sebetralstat as first-line, suggests ecallantide as a second-line option only when first-line therapies are not available or feasible, and recommends solvent detergent-treated plasma or fresh frozen plasma as third-line; it states that direct comparisons among these options are limited, and recommends intravenous plasma-derived C1-INH as first-line for pregnant patients. The guideline by Betschel et al. lists ecallantide, icatibant, intravenous C1INH, and sebetralstat as effective therapies, discussed “without implying any hierarchy of preference”, and states that access to another effective acute treatment is crucial given variation in patient response. A pediatric guideline recommends icatibant, intravenous plasma-derived C1-INH, or recombinant C1-INH as first-line acute treatment for children aged 2 to 12 years, and ecallantide, icatibant, either intravenous C1-INH, or sebetralstat for adolescents aged 12 years or older.

The guidelines recommend that all attacks be considered for on-demand treatment and treated as early as possible, that every patient have medication for at least 2 attacks, kept at home, and that patients carry on-demand medication at all times; the US HAEA Medical Advisory Board recommends that all patients with HAE due to C1-INH deficiency have access to at least two standard doses. Upper airway swelling calls for on-demand treatment as early as possible and emergency care, and all patients with laryngeal edema are to be assessed in the emergency department even after self-therapy. The Vázquez et al. guideline states that the only oral on-demand treatment available is sebetralstat and that long-term data for it are still lacking. Deucrictibant appears in none of the guidelines' lists of recommended agents; the Vázquez et al. guideline states that preliminary results have demonstrated its efficacy for treating attacks, and the pediatric guideline notes that RAPIDe-3 is evaluating it in adolescent and adult patients.

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8); [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/); [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/); [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)

<a id="topic-2.2.2.2-2"></a>

### Summary: anticipated use of an oral on-demand option and care setting

Deucrictibant is described as the first and only orally administered bradykinin B2 receptor antagonist investigated for on-demand treatment of HAE attacks. In RAPIDe-3, participants self-administered the study drug during or immediately after a qualification call with the investigator, and in Part 2 of RAPIDe-1 participants self-administered it at home. Adolescents with laryngeal attacks of any severity and adults with severe laryngeal attacks were instructed to take their conventional on-demand therapy instead of the study drug and to seek medical care urgently. One publication notes that the recommendation to treat all attacks as early as possible shaped the design of recent trials, including those of sebetralstat and deucrictibant.

The trial investigators state that an efficacious oral on-demand option with a favourable safety profile “could address key unmet needs”, and that further studies of patient preferences, including number of pills administered per dose, are warranted. A guideline states that HAE is well suited to self-treatment, especially by oral administration, and that injectable therapies can pose barriers such as needle phobia, poor venous access, or impaired dexterity; ecallantide must be administered under the supervision of health care personnel. The sponsor intends to file for approval of and commercialize deucrictibant immediate-release capsules as an on-demand treatment for HAE attacks through its own commercial infrastructure, states that an oral on-demand treatment could decrease the burden of therapy through easier administration, portability, and discretion, and states its belief that deucrictibant could become standard of care for on-demand treatment. The sponsor is also preparing an NDA for the extended-release tablet for prophylaxis, which reduced the mean monthly attack rate by 83% in CHAPTER-3, with submission planned for 1H2027; these data concern the extended-release tablet.

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext); [Cohn et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39724968/); [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.2.2.2-3"></a>

### Summary: patient and physician preference

In a study in which Pharvaris participated in the interpretation of the data, 225 physicians completed patient record forms for 1131 patients and 279 patients completed a questionnaire; 84% of patients in the patient-reported group indicated that, given the choice, they would prefer to take their on-demand treatment by mouth. The top physician-reported unmet needs of on-demand treatment were a different route of administration (320/817 [39%]), discomfort upon administration (112/817 [14%]), and injection site reactions (111/817 [14%]); patients most often reported not liking injections and experiencing pain, bruising, or burning with injections (42/227 [19%] each), followed by not liking to inject medications in public places (38/227 [17%]). In interviews with 25 US and UK patients and caregivers, in a study supported by KalVista Pharmaceuticals, all participants expressed interest in an oral on-demand treatment, and 8 indicated that they would treat attacks earlier with one; more than half regarded the need to swallow a tablet as a potential disadvantage during a throat or facial attack, and some were concerned about how quickly an oral tablet would begin to work.

Source: [Anderson et al. (2026b)](https://link.springer.com/article/10.1007/s12325-026-03790-2); [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/)

<a id="topic-2.2.2.2-4"></a>

### Summary: payer criteria and quantity limits

Published payer policies refer to generic icatibant in their criteria for on-demand treatment, including sebetralstat (Ekterly). Cigna requires prior authorization, with coverage for patients aged 12 to under 18 years, patients who have previously treated an attack with Ekterly, or patients who have tried generic icatibant; its quantity limits allow treatment of 4 attacks per 28 days at the maximum Ekterly dose, with an override for an additional 4 attacks each month and a one-time override of 16 additional tablets. Univera Healthcare requires documentation of therapeutic failure, severe intolerance, or a contraindication to generic icatibant for Ekterly requests in patients 18 years of age and older, lists a quantity limit of 4 tablets per 30 days, authorizes one acute HAE medication at one time, and does not approve requests for quantities in excess of its limits. A Regence policy requires documentation that generic icatibant and either Berinert or Ruconest have been ineffective, not tolerated, or contraindicated, authorizes acute treatments in a quantity sufficient for three attacks per month, or four to six attacks per month when its criteria are met (including, for HAE types I and II, evaluation for prophylactic therapy), and states that “Generic icatibant is the lowest cost of all available options.”

Source: [Cigna Ekterly prior authorization policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0756_coveragepositioncriteria_hereditary_angioedema_ekterly.pdf); [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf); [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf); [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf)

<a id="topic-2.2.2.2-5"></a>

### First-line on-demand treatment options: WAO guideline

> “We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.”
> “Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide”
> “Direct comparisons among these options are limited.”
> “We suggest considering ecallantide as a second-line option for ODT for HAE attacks only when first-line therapies are not available or feasible.”
> “We recommend SDP/FFP as third-line treatment, with SDP preferred over FFP if available due to a lower risk of viral transmission.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-6"></a>

### Oral on-demand treatment in the WAO guideline

> “The only oral ODT available is sebetralstat and the dose is 2 300 mg tablets.”
> “Sebetralstat, an oral plasma kallikrein inhibitor, was recently approved by the United States Food and Drug Administration (FDA) as an ODT for HAE, based on the findings of the KONFIDENT study”
> “long-term data from extension studies and RWE are still lacking, precluding appropriate comparisons between this novel agent and existing first-line ODT options.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-7"></a>

### Effective acute therapies: International/Canadian guideline

> “Effective therapies should be used for the acute treatment of attacks of angioedema to reduce duration and severity of attacks. Effective therapies include ecallantide, icatibant, intravenous C1INH (plasma-derived or recombinant), and sebetralstat.”
> “The following therapies are discussed in alphabetical order, without implying any hierarchy of preference.”
> “Given the variation in patient response to acute therapies [53], it is crucial that healthcare professionals have access to another effective acute treatment, if necessary, to optimize patient outcomes.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.2-8"></a>

### Treatment of every attack as early as possible: guideline recommendations

> “We recommend that ODT be considered for all HAE attacks, which is mandatory when upper airway involvement is detected, and should be instituted as early as possible.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend that all attacks are considered for on-demand treatment.”
> “We recommend that attacks are treated as early as possible.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “Attacks should be treated early to reduce morbidity.”
> “Attacks should be treated early to reduce mortality.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.2-9"></a>

### On-demand medication at home for at least two attacks: guideline recommendations

> “We recommend that every patient, even if asymptomatic, must have ODT available at home because the risk of a serious attack is unpredictable and persists throughout their lifetime.”
> “HAE attacks can follow an unpredictable clinical course, rebound is possible, and multiple attacks can appear in quick succession. Therefore, patients should always have enough medication available to treat at least 2 acute attacks at home.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend that all patients have sufficient medication for on-demand treatment of at least two attacks and carry on-demand medication at all times.”
> “In patients with frequent attacks, the time it takes to obtain more on-demand medication should be taken into consideration in the provision of treatment, so that they never run out of on-demand medication.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “All patients should have access to at least two doses of acute therapy, and their ability to administer these therapies should be routinely assessed.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

> “Based on the US HAEA Medical Advisory Board recommendations, all patients with HAE due to C1-Inhibitor deficiency should have access to at least two (2) standard doses of a medication proven effective in treating HAE attacks.”

Source: [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)

<a id="topic-2.2.2.2-10"></a>

### Pediatric guideline: first-line acute treatment by age

> “In children with hereditary angioedema due to C1 inhibitor deficiency aged between 2 and 12 years, we recommend the use of icatibant, intravenous plasma‐derived C1 inhibitor concentrate, or intravenous recombinant human C1 inhibitor as first‐line therapy for acute treatment of angioedema attacks.”
> “In adolescents with hereditary angioedema due to C1 inhibitor deficiency aged 12 years or older, we recommend the use of ecallantide, icatibant, intravenous plasma‐derived C1 inhibitor concentrate, intravenous recombinant human C1 inhibitor, or sebetralstat as first‐line therapy for acute treatment of angioedema attacks.”
> “We recommend acute treatment of angioedema attacks in pediatric patients with hereditary angioedema as early as possible.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.2-11"></a>

### Upper airway attacks: emergency care setting

> “We recommend that in the case of upper airway swelling, ODT should be given as early as possible, and patients should seek emergency care.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “All attacks of angioedema involving the upper airway are medical emergencies and must be treated immediately.”
> “It is also recommended that all patients with laryngeal edema, even following self-therapy, be assessed in the emergency department, in case the angioedema does not respond to therapy and expertise in airway management is required”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.2-12"></a>

### Phase 3 trial instructions for laryngeal attacks

> “Adolescent participants with laryngeal attacks, regardless of severity, and adult participants with severe laryngeal attacks (those with symptoms of breathing difficulties or stridor) were instructed to immediately take their conventional on-demand therapy instead of the study drug and to seek medical care urgently.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.2-13"></a>

### Care setting: self-administration at home in deucrictibant trials

> “During the qualification call with the investigator or immediately following, patients then self-administered the study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

> “In Part 2, patients were instructed to self-administer deucrictibant at home in the assigned treatment sequence to treat three investigator-confirmed qualifying attacks”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.2.2.2-14"></a>

### Care setting: agents requiring administration by health care personnel

> “Due to the risk of hypersensitivity reactions, ecallantide must be administered only under the supervision of healthcare personnel.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “Both FP and SDP are only available for in-hospital use, and there can be significant delays”
> “sometimes up to 24 h”
> “in obtaining these products”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.2-15"></a>

### Oral administration and self-treatment: International/Canadian guideline

> “Several characteristics of HAE make it particularly well-suited for self-treatment via SC, IV, and especially oral administration.”
> “However, injectable therapies can pose barriers to some patients due to factors such as needle phobia, poor venous access, or impaired dexterity, which can make SC/IV self-administration difficult.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.2-16"></a>

### Evolution of on-demand treatment guidelines and trial design

> “In 2013, the US Hereditary Angioedema Association guidelines recommended that all attacks, irrespective of location or severity, be considered for treatment as early as possible after onset to minimize morbidity and mortality.”
> “This approach remains the cornerstone of current treatment guidelines and has shaped the design of recent clinical trials, such as those for the investigational agents, oral plasma kallikrein inhibitor sebetralstat and oral bradykinin B2 receptor antagonist deucrictibant.”

Source: [Cohn et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39724968/)

<a id="topic-2.2.2.2-17"></a>

### Deucrictibant in guideline and review discussion

> “Two distinct formulations are being investigated: immediate-release capsule (previously referred to as PHVS416) and extended-release tablet (previously referred to as PHVS719).”
> “Preliminary study results on the use of deucrictibant for the treatment of HAE attacks have demonstrated its efficacy.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “RAPIDe‐3 is evaluating an oral BDKRB2 antagonist (deucrictibant) in adolescent and adult patients”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

> “Published and ongoing clinical studies demonstrate favorable safety, tolerability, and efficacy profiles for both LTP and ODT, offering a convenient oral alternative that may reduce treatment burden and improve patient quality of life.”

Source: [Bui et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42635583/)

<a id="topic-2.2.2.2-18"></a>

### Trial investigators' statement on the role of an oral on-demand option

> “An oral therapy option for on-demand treatment of hereditary angioedema attacks that is efficacious, with a favourable safety profile, could address key unmet needs in the management of bradykinin-mediated angioedema, including improving symptom control as guidelines recommend.”
> “Further studies are warranted to explore patient preferences and effects on clinical outcomes of different oral on-demand therapies, including number of pills administered per dose.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.2-19"></a>

### Company statements on intended positioning

> “Most on-demand therapies are administered by injection, the burden of which causes people to delay or forego treatment of their attacks. An oral on-demand treatment could decrease the burden of therapy by improving convenience through easier administration, portability, and discretion.”
> “With the encouraging RAPIDe-3 results, combined with the trusted bradykinin B2 receptor antagonist mechanism seen in both icatibant and deucrictibant, we believe deucrictibant could become standard of care for on-demand treatment.”
> “According to our analysis, oral therapy remains the highest unmet need for both on-demand and prophylactic use in AE-BK.”
> “We intend to file for approval and commercialize deucrictibant IR capsules as a fast-acting, orally available, potent inhibitor and selective on-demand treatment for HAE attacks.”
> “If any of our product candidates receive marketing approval, we intend to market, sell and distribute them using our own commercial infrastructure.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “If approved, deucrictibant could potentially address unmet needs across both on-demand and long-term prophylaxis of bradykinin-mediated angioedema attacks”
> “our team is preparing for our potential first commercial launch and is well on its way to building an experienced commercial team.”
> “By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.2.2.2-20"></a>

### Company statement: deucrictibant XR prophylaxis development

> “Treatment with deucrictibant XR in participants with all types of HAE reduced the mean monthly attack rate by 83% (p<0.0001)”
> “Preparation of NDA dossier of deucrictibant XR for prophylaxis of AE-BK attacks ongoing; timeline remains on-track for submission in 1H2027”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.2.2.2-21"></a>

### Patient and physician survey: preference for oral on-demand treatment, Pharvaris-supported analysis

> “Participating physicians (n = 225) completed PRFs for 1131 patients (age range: 3–82 years); 279 patients completed the questionnaire.”
> “The top three physician-reported unmet needs of ODT included different route of administration (320/817 [39%]), discomfort upon administration (112/817 [14%]), and injection site reactions (111/817 [14%])”
> “The patient-reported top three unmet needs of ODT were not liking injections, experiencing pain/bruising/burning with injections (42/227 [19%] each), and not liking to inject medications in public places (38/227 [17%])”
> “In the patient-reported group, 84% of patients indicated that, given the choice, they would prefer to take their ODT by mouth.”
> “Pharvaris participated in the interpretation of the data and the review and approval of this manuscript”

Source: [Anderson et al. (2026b)](https://link.springer.com/article/10.1007/s12325-026-03790-2)

<a id="topic-2.2.2.2-22"></a>

### Qualitative interviews: perceptions of an oral on-demand treatment

> “All participants expressed interest in an oral on-demand treatment when asked directly, with some suggesting this spontaneously during interviews while discussing the difficulties with their current injectable treatments. Participants indicated that if they had oral on-demand treatment available, they would treat attacks earlier (n = 8).”
> “More than half of participants believed the need to swallow a tablet was a potential disadvantage if they were having a throat or facial attack.”
> “Some participants expressed concerns about the speed at which an oral tablet would begin to work, as a pill needs to dissolve to enter the blood stream, unlike injectable medications.”

Source: [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/)

<a id="topic-2.2.2.2-23"></a>

### Case series: reasons for switching to an oral on-demand treatment

> “Reasons for switching were administration-related treatment barriers (8/12 [66.7%]), improved lifestyle compatibility(6/12 [50.0%]), and enhanced treatment autonomy (5/12 [41.7%]).”

Source: [Lochbaum et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43025858/)

<a id="topic-2.2.2.2-24"></a>

### Payer step therapy and quantity limits for oral on-demand treatment: Regence

> “Clinical documentation (such as chart notes) confirming that treatment with the following has been ineffective, not tolerated, or contraindicated: 1. Generic icatibant. AND 2. At least one of the following (a or b): a. Berinert (plasma-derived C1-INH) OR b. Ruconest (recombinant C1-INH)”
> “Initial quantities: Acute treatments for HAE may be authorized in a quantity sufficient for the treatment of three attacks per month.”
> “Higher quantities: Acute treatments for HAE may be authorized in a quantity sufficient for the treatment of four to six attacks per month when all criteria (1 through 3) below are met:”
> “For HAE types I and II only: Documentation that the patient is being evaluated for initiation of prophylactic HAE-specific therapy.”
> “Generic icatibant is the lowest cost of all available options.”

Source: [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf)

<a id="topic-2.2.2.2-25"></a>

### Payer quantity limits for oral on-demand treatment: Cigna drug quantity management

> “The quantity limits outlined below provide for the patient to treat 4 attacks (at the maximum Ekterly dose) per 28 days, with an override provided to treat an additional 4 attacks (at the maximum Ekterly dose) each month.”
> “If the patient requires additional doses of Ekterly to treat a subsequent attack of hereditary angioedema (HAE), approve a one-time override for 16 additional tablets at retail or home delivery.”

Source: [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf)

<a id="topic-2.2.2.2-26"></a>

### Payer preferred product criteria for oral on-demand treatment: Cigna prior authorization

> “Prior Authorization is required for benefit coverage of Ekterly.”
> “Patient meets one of the following (1, 2, or 3): 1. Patient is ≥ 12 years of age and ˂ 18 years of age. 2. Patient has previously treated an acute HAE attack with Ekterly. 3. Patient has tried generic icatibant”

Source: [Cigna Ekterly prior authorization policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0756_coveragepositioncriteria_hereditary_angioedema_ekterly.pdf)

<a id="topic-2.2.2.2-27"></a>

### Payer step therapy and quantity limits for on-demand treatments: Univera Healthcare

> “For patients 18 years of age and older, requests for Ekterly will require documentation of therapeutic failure, severe intolerance, OR a contraindication to generic icatibant.”
> “Quantity limit of 4 tablets per 30 days.”
> “Quantity limit of #3 (3ml each) pre-filled syringes – 9ml/30 days.”
> “Quantity limit of 10 vials per 30 days on Rx benefit”
> “Individuals will only be authorized for one acute HAE medication at one time.”
> “Due to lack of evidence for more frequent administration, requests for quantities in excess of the established limits will not be approved.”

Source: [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf)

Additional sources: [Zuraw and Christiansen (2026)](https://pubmed.ncbi.nlm.nih.gov/42849490/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
